Inhibikase Therapeutics (IKT) risk factors

Item 1A of every Inhibikase Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open IKT in Gloom →

Inhibikase Therapeutics' chart, financials and news, free in your browser.Open IKT in Gloom →

FY2025 10-K risk factors
98 risks15 new19 dropped35 reworded
Clinical losses reached $48.3M in 2025, driven by the global Phase 3 trial for IKT-001 in PAH. Regulatory and data-transfer restrictions under new DOJ rules and U.S. government march-in rights threaten operations. Co-owned patents with Sphaera Pharma and reliance on AI tools increase legal and compliance exposure.
Filed Mar 26, 2026
FY2024 10-K risk factors
102 risks
Clinical-stage drug development relies entirely on external capital, grants, and successful trials for survival.
Filed Mar 27, 2025